|
|
|
|
||
Re: One more call observation: atypical dosing in ARO-HBV could lead to more potent effects?Yes very ballsy! I guess what they took from the DPC fiasco is that it is better to get the efficacy data while you can. Sort of like a "do it now and ask for forgiveness later" approach. That sounds very Anzalone! Trying to manage my position size accordingly. That's not all that easy but will certainly take advantage of any strength going into Oct 16. |
return to message board, top of board |